Dapagliflozin meets diabetes endpoints

Bristol-Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) said dapagliflozin plus metformin met the primary endpoint of non-inferiority to glipizide plus metformin in change from baseline in HbA1c at week 52 in a Phase III trial to treat Type II diabetes (0.52% for each). Dapagliflozin plus metformin also met the secondary endpoint of significantly reducing weight loss from baseline to week 52 vs. glipizide plus metformin (3.22 kg reduction vs. 1.44 kg increase, p<0.0001). The double-blind trial enrolled 814 patients with Type II diabetes inadequately controlled with metformin. Data were presented at the European Association for the Study of Diabetes meeting in Stockholm. ...